Department of Pathology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, Netherlands.
BMJ. 2010 Mar 11;340:c1040. doi: 10.1136/bmj.c1040.
To determine whether offering self sampling of cervicovaginal material for high risk human papillomavirus (HPV) testing is an effective screening method for women who do not attend regular cervical screening programmes.
Cohort study (the PROHTECT trial). Settings Noord-Holland and Flevoland regions of the Netherlands, December 2006 to December 2007, including 13 laboratories, gynaecologists, and more than 800 general practitioners.
28 073 women who had not responded to two invitations to the regular cervical screening programme: 27 792 women were assigned to the self sampling group and invited to submit a self collected cervicovaginal sample for HPV testing; 281 were assigned to the recall control group and received a second re-invitation for conventional cytology.
Women with a positive result on the high risk HPV test on their self sample material were referred to their general practitioner. Women with abnormal results on cytology were referred for colposcopy. Women with normal results on cytology were re-evaluated after one year by cytology and high risk HPV testing and referred for colposcopy if either result was positive.
Attendance rate in both groups and yield of cervical intraepithelial neoplasia grade II/III or worse (>or=CIN II/>or=CIN III) in self sampling responders.
The compliance rate in the self sampling group was significantly higher than in the control group (crude 26.6% v 16.4%, P<0.001; adjusted 27.5% v 16.6%, P<0.001). The number of detected >or=CIN II and >or=CIN III lesions in self sampling responders was 99 (1.3%) and 76 (1.0%), respectively. Self sampling responders who had not participated in the previous round of screening (43%) had increased relative risks of >or=CIN II (2.04, 95% confidence interval 1.27 to 3.28) and >or=CIN III (2.28, 1.31 to 3.96) compared with self sampling women who had been screened in the previous round (57%).
Offering self sampling by sending a device for collecting cervicovaginal specimens for high risk HPV testing to women who did not attend regular screening is a feasible and effective method of increasing coverage in a screening programme. The response rate and the yield of high grade lesions support implementation of this method for such women. Trial registration ISRCTN45527158.
确定对未参加常规宫颈癌筛查项目的女性进行高危型人乳头瘤病毒(HPV)自我采样检测是否为一种有效的筛查方法。
队列研究(PROHTECT 试验)。地点荷兰北荷兰省和弗莱福兰省,2006 年 12 月至 2007 年 12 月,包括 13 个实验室、妇科医生和 800 多名全科医生。
28073 名未回应两次常规宫颈癌筛查项目邀请的女性:27792 名女性被分配到自我采样组,并被邀请提交自行采集的宫颈阴道样本进行 HPV 检测;281 名女性被分配到召回对照组,并收到第二次常规细胞学检查的重新邀请。
对高危 HPV 检测结果阳性的自我采样女性,由其全科医生进行处理。细胞学检查结果异常的女性接受阴道镜检查。细胞学检查结果正常的女性在一年后再次通过细胞学和高危 HPV 检测进行评估,如果结果阳性则进行阴道镜检查。
两组的参与率以及自我采样组中宫颈上皮内瘤变 2/3 级或更高级别(>或=CIN2/ >或=CIN3)的检出率。
自我采样组的依从率明显高于对照组(粗率 26.6%比 16.4%,P<0.001;校正率 27.5%比 16.6%,P<0.001)。自我采样组中检出的 >或=CIN2 和 >或=CIN3 病变分别为 99 例(1.3%)和 76 例(1.0%)。与上一轮筛查中接受过筛查的自我采样女性(57%)相比,未参加上一轮筛查的自我采样组女性(43%)的 CIN2 相对风险增加 2.04(95%置信区间 1.27 至 3.28),CIN3 相对风险增加 2.28(95%置信区间 1.31 至 3.96)。
向未参加常规筛查的女性发送高危型 HPV 检测用宫颈阴道标本采集装置进行自我采样是提高筛查计划覆盖率的一种可行且有效的方法。该方法的应答率和高级别病变的检出率支持对这类女性实施该方法。试验注册 ISRCTN45527158。